WNK2 and glioblastoma: Mitogen-activated protein kinase kinase (MAPKK/MEK) inhibition however only reduced growth of a small subset of NF1-deficient GBM cell lines [31] and the multi-kinase inhibitor sorafenib failed to enhance radio- and chemosensitivity of GBM cell lines [32].